Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Apr;96(17):e6680.
doi: 10.1097/MD.0000000000006680.

The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas

Qi Shen  1 , Li Shu, Hui Luo, Xiaoli Hu, Xueqiong Zhu
Affiliations
Observational Study

The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas

Qi Shen et al. Medicine (Baltimore). 2017 Apr.

Abstract

To investigate the association between widespread use of mifepristone in abortions and risk of uterine leiomyomas.We conducted a case-control study of 305 patients with uterine leiomyomas between January 2011 and July 2012; 311 women with ordinary vaginitis were selected as controls during the same period. Data were collected by questionnaires (including past history, life history, menstruation history, reproductive history, abortion history, the use of mifepristone, and uterine leiomyomas risk factors) and calculated by univariate and multivariate conditional logistic regression analyses; odds ratios and its 95% confidence interval were calculated to estimate the risk for uterine leiomyomas.Abortion with mifepristone was one of the risk factors for uterine leiomyomas, and the risk increased with increasing frequency of mifepristone use. Family history of uterine leiomyomas, body mass index, age at menarche, number of full-term delivery, and medical abortion history were also correlated with uterine leiomyomas.The use of mifepristone in abortion will increase the risk to develop uterine leiomyomas.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Okolo S. Incidence aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:571–88. - PubMed
    1. Ishikawa H, Ishi K, Serna VA, et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 2010;151:2433–42. - PMC - PubMed
    1. Stein K, Ascher-Walsh C. A comprehensive approach to the treatment of uterine leiomyomata. Mt Sinai J Med 2009;76:546–56. - PubMed
    1. Eisinger SH, Fiscella J, Bonfiglio T, et al. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 2009;146:215–8. - PubMed
    1. Shen Q, Hua Y, Jiang W, et al. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril 2013;100:1722–6. - PubMed

Publication types

MeSH terms